| |
GeneSuites is the development manager for Catalyst BioCampus in North Carolina which is on track to support biomanufacturing by 2024. Learn more.
|
|
Today's Big NewsNov 30, 2022 |
| By Annalee Armstrong Two deaths have dimmed the initial glow surrounding Eisai and Biogen’s next Alzheimer’s disease therapy lecanemab. But the Japanese company now has more answers on the risks patients may need to learn to accept to receive treatment. |
|
|
|
By Angus Liu Rare disease drug maker Horizon Therapeutics said it has drawn buyout interest from pharma juggernauts Amgen, Johnson & Johnson and Sanofi, all of which arguably have good reasons to make an M&A move. |
By Heather Landi UnitedHealth Group expects double-digit revenue growth in 2023, with the company's top line protected to come in between $357 billion and $360 billion next year, the company announced Tuesday. |
By Andrea Park Amazon Web Services unveiled a new cloud computing service this week that aims to give researchers and scientists in life sciences and healthcare a sturdier option for storing and analyzing mass amounts of individual health data. |
|
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now.
|
|
By Nick Paul Taylor Sanofi’s oral sleeping sickness candidate acoziborole has achieved 95% efficacy in a late-phase clinical trial, delivering a boost to a global push to interrupt transmission of the parasitic disease by 2030. |
By Zoey Becker After five years of Dupixent’s reign for Sanofi, the U.K.'s medicines regulatory agency is warning about risks of ocular side effects. The regulator asked patients and healthcare providers to look out for sudden changes in vision or eye pain after treatment. Patients are asked to “promptly report” new or worsening symptoms. |
By Conor Hale The collaboration will see CMR and Ethicon’s sales teams offer their respective portfolios bundled together, starting in select hospitals in Europe and Brazil. |
By Frank Diamond Vaccinated individuals still stand a much greater chance of surviving COVID-19 than unvaccinated individuals. Still, scientists keep a wary eye on troublesome trends. |
By Annalee Armstrong Janssen has picked a tau vaccine from its collaboration with neurodegenerative-focused biotech AC Immune to advance into further development. |
By Kevin Dunleavy Catalent is laying off more than 210 workers at two sites in Maryland and one in Texas according to Worker Adjustment and Retraining Notifications (WARN) posted in the states. The company also is reducing 400 staffers at its sprawling site in Bloomington, Indiana. The layoffs come as the company is cutting costs as revenue from COVID-19 products is in sharp decline. |
By Andrea Park “What we've shown is a chest X-ray is more than a chest X-ray,” said Jakob Weiss, M.D., lead author of the study . |
By Dave Muoio The agency published a memo Monday reminding hospitals of their "regulatory obligation" to safety practices as well as their healthcare workers' right "to provide care in a safe setting." |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about the rise of virtual care since the pandemic started and what its role will be moving forward. We also discuss some tactics to control rising drug prices in the U.S., like changing PBMs' business model and new companies like the one from billionaire entrepreneur Mark Cuban. |
|
|---|
|
|
|
Tuesday, December 7th, 2022 | 10am ET/7am PT In this presentation we’ll review how we established GOCHO™ cells from an adherent CHO-K1 cell line to meet current industry standards, how the choice of cloning media drove cell culture media choices for the entire cell-line development process, and more. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
